Improved Quantification of <sup>18</sup>F-FDG PET during <sup>131</sup>I-Rituximab Therapy on Mouse Lymphoma Models after <sup>131</sup>I Prompt Emission Correction
<sup>18</sup>F-FDG Positron Emission Tomography (PET) is used to monitor tumor response to <sup>131</sup>I-therapy, but is confounded by prompt emissions (284, 364, 637, and 723 keV) from <sup>131</sup>I, particularly in animal PET imaging. We propose a method for...
Main Authors: | , , |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2019-10-01
|
Series: | Diagnostics |
Subjects: | |
Online Access: | https://www.mdpi.com/2075-4418/9/4/144 |
_version_ | 1811298273454981120 |
---|---|
author | Young Sub Lee Hee-Joung Kim Jin Su Kim |
author_facet | Young Sub Lee Hee-Joung Kim Jin Su Kim |
author_sort | Young Sub Lee |
collection | DOAJ |
description | <sup>18</sup>F-FDG Positron Emission Tomography (PET) is used to monitor tumor response to <sup>131</sup>I-therapy, but is confounded by prompt emissions (284, 364, 637, and 723 keV) from <sup>131</sup>I, particularly in animal PET imaging. We propose a method for correcting this emission in <sup>18</sup>F-FDG PET. The <sup>131</sup>I prompt emission effect was assessed within various energy windows and various activities. We applied a single gamma correction method to a phantom and in vivo mouse model. The <sup>131</sup>I prompt emission fraction was 12% when 300 µCi of <sup>131</sup>I and 100 µCi of FDG were administered, and increased exponentially with escalating <sup>131</sup>I activity for all energy windows. The difference in spill-over ratio was reduced to <5% after <sup>131</sup>I prompt emission correction. In the mouse model, the standard uptake value (SUV) did not differ significantly between FDG PET only (gold standard) and FDG PET after <sup>131</sup>I prompt emission-correction, whereas it was overestimated by 38% before correction. Contrast was improved by 18% after <sup>131</sup>I prompt emission correction. We first found that count contamination on <sup>18</sup>F-FDG follow-up scans due to <sup>131</sup>I spilled-over count after <sup>131</sup>I rituximab tumor targeted therapy. Our developed <sup>131</sup>I prompt emission-correction method increased accuracy during measurement of standard uptake values on <sup>18</sup>F-FDG PET. |
first_indexed | 2024-04-13T06:17:02Z |
format | Article |
id | doaj.art-23d10db558204f1e9ccaf6b1cdeeea54 |
institution | Directory Open Access Journal |
issn | 2075-4418 |
language | English |
last_indexed | 2024-04-13T06:17:02Z |
publishDate | 2019-10-01 |
publisher | MDPI AG |
record_format | Article |
series | Diagnostics |
spelling | doaj.art-23d10db558204f1e9ccaf6b1cdeeea542022-12-22T02:58:47ZengMDPI AGDiagnostics2075-44182019-10-019414410.3390/diagnostics9040144diagnostics9040144Improved Quantification of <sup>18</sup>F-FDG PET during <sup>131</sup>I-Rituximab Therapy on Mouse Lymphoma Models after <sup>131</sup>I Prompt Emission CorrectionYoung Sub Lee0Hee-Joung Kim1Jin Su Kim2Division of RI Application, Korea Institute Radiological and Medical Sciences, Seoul 01812, KoreaDepartment of Radiation Convergence Engineering and Research Institute of Health Science, Yonsei University, Wonju 26493, KoreaDivision of RI Application, Korea Institute Radiological and Medical Sciences, Seoul 01812, Korea<sup>18</sup>F-FDG Positron Emission Tomography (PET) is used to monitor tumor response to <sup>131</sup>I-therapy, but is confounded by prompt emissions (284, 364, 637, and 723 keV) from <sup>131</sup>I, particularly in animal PET imaging. We propose a method for correcting this emission in <sup>18</sup>F-FDG PET. The <sup>131</sup>I prompt emission effect was assessed within various energy windows and various activities. We applied a single gamma correction method to a phantom and in vivo mouse model. The <sup>131</sup>I prompt emission fraction was 12% when 300 µCi of <sup>131</sup>I and 100 µCi of FDG were administered, and increased exponentially with escalating <sup>131</sup>I activity for all energy windows. The difference in spill-over ratio was reduced to <5% after <sup>131</sup>I prompt emission correction. In the mouse model, the standard uptake value (SUV) did not differ significantly between FDG PET only (gold standard) and FDG PET after <sup>131</sup>I prompt emission-correction, whereas it was overestimated by 38% before correction. Contrast was improved by 18% after <sup>131</sup>I prompt emission correction. We first found that count contamination on <sup>18</sup>F-FDG follow-up scans due to <sup>131</sup>I spilled-over count after <sup>131</sup>I rituximab tumor targeted therapy. Our developed <sup>131</sup>I prompt emission-correction method increased accuracy during measurement of standard uptake values on <sup>18</sup>F-FDG PET.https://www.mdpi.com/2075-4418/9/4/144<sup>18</sup>f-fdg petpersonalized medicine<sup>131</sup>i prompt emission-correctionradioimmunotherapyrituximabrituxan |
spellingShingle | Young Sub Lee Hee-Joung Kim Jin Su Kim Improved Quantification of <sup>18</sup>F-FDG PET during <sup>131</sup>I-Rituximab Therapy on Mouse Lymphoma Models after <sup>131</sup>I Prompt Emission Correction Diagnostics <sup>18</sup>f-fdg pet personalized medicine <sup>131</sup>i prompt emission-correction radioimmunotherapy rituximab rituxan |
title | Improved Quantification of <sup>18</sup>F-FDG PET during <sup>131</sup>I-Rituximab Therapy on Mouse Lymphoma Models after <sup>131</sup>I Prompt Emission Correction |
title_full | Improved Quantification of <sup>18</sup>F-FDG PET during <sup>131</sup>I-Rituximab Therapy on Mouse Lymphoma Models after <sup>131</sup>I Prompt Emission Correction |
title_fullStr | Improved Quantification of <sup>18</sup>F-FDG PET during <sup>131</sup>I-Rituximab Therapy on Mouse Lymphoma Models after <sup>131</sup>I Prompt Emission Correction |
title_full_unstemmed | Improved Quantification of <sup>18</sup>F-FDG PET during <sup>131</sup>I-Rituximab Therapy on Mouse Lymphoma Models after <sup>131</sup>I Prompt Emission Correction |
title_short | Improved Quantification of <sup>18</sup>F-FDG PET during <sup>131</sup>I-Rituximab Therapy on Mouse Lymphoma Models after <sup>131</sup>I Prompt Emission Correction |
title_sort | improved quantification of sup 18 sup f fdg pet during sup 131 sup i rituximab therapy on mouse lymphoma models after sup 131 sup i prompt emission correction |
topic | <sup>18</sup>f-fdg pet personalized medicine <sup>131</sup>i prompt emission-correction radioimmunotherapy rituximab rituxan |
url | https://www.mdpi.com/2075-4418/9/4/144 |
work_keys_str_mv | AT youngsublee improvedquantificationofsup18supffdgpetduringsup131supirituximabtherapyonmouselymphomamodelsaftersup131supipromptemissioncorrection AT heejoungkim improvedquantificationofsup18supffdgpetduringsup131supirituximabtherapyonmouselymphomamodelsaftersup131supipromptemissioncorrection AT jinsukim improvedquantificationofsup18supffdgpetduringsup131supirituximabtherapyonmouselymphomamodelsaftersup131supipromptemissioncorrection |